SSSara Shafieipour

Sara Shafieipour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara Shafieipour has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of a patient with primary adenocarcinoma of the proximal third of the esophagus: a case report

    by Ali Saeidpour Parizi, Ahmad Enhesari, Vahid Moazed, Sara Shafieipour, Samira Shahba, Alaa Hamza Hermis, Mohammad Ali Zakeri

    Cervical esophageal adenocarcinoma is a rare tumor often associated with Barrett’s esophagus, and its prevalence is lower than distal esophageal adenocarcinoma. Upper esophageal malignancies are usually squamous cell carcinomata; about 5% of these cases are seen during upper gastrointestinal endoscopy. We present a patient (a 39-year-old Iranian man) with invasive adenocarcinoma of the proximal third of the esophagus, who was referred to the hospital with no endoscopic or histopathologic evidence of Barrett’s esophagus. We discuss the probable cause of this tumor and treatment options and emphasize the importance of recognizing and managing this rare disease. This case highlights the rarity of this adenocarcinoma and emphasizes the potential of chemotherapy as a standalone treatment, as well as the need for personalized therapeutic strategies and further research for the management of esophageal cancer.

  • Open Access

    COVID-19 and Upper Gastrointestinal Bleeding; Etiology, Risk Factors, and Outcomes: A Case-Control Study

    by Sara Shafieipour, Mohammad Rezaei Zadeh Rukerd, Niloofar Farsiu, Mohsen Nakhaie, Samaneh Jahangiri, Maysam Yousefi, Hanieh Mirkamali, Aryan Mohamadinezhad

    Background: COVID-19-associated gastrointestinal (GI) symptoms are often self-limiting; however, gastrointestinal bleeding (GIB) is a critical complication in patients with COVID-19. The present study investigates the etiology, risk factors, esophagogastroduodenoscopy (EGD) findings, and outcomes associated with upper gastrointestinal bleeding (UGIB) in hospital inpatients with COVID-19. Methods: In this retrospective case-control study, 127 patients with COVID-19 in Kerman, Iran, were diagnosed using reverse transcription polymerase chain reaction (RT-PCR) and subsequently divided into case and control groups from January 2022 to July 2022. Results: This study evaluated 64 patients with COVID-19 with UGIB and 63 patients without. The case group reported previous history of GIB and cirrhosis at 17.2% and 12.5%, respectively (P=0.001 and P=0.01). Melena (37.5%) and peptic ulcer (21.87%) were the most common UGIB symptom and EGD findings, respectively. In the comparison of the case group with the control group, the duration of the patient’s stay in the intensive care unit (ICU) (11.58±1.13 vs. 8.29±1.06 days), the need for invasive mechanical ventilation (IMV) (17.2% vs. 8.1%), and the mortality rate (26.6% vs. 18.9%) were recorded (P=0.03, 0.124, and 0.07, respectively). Conclusion: Patients with COVID-19 and UGIB have a more prevalent ICU stay compared with those without. Melena and peptic ulcer were the most common presentations and EGD findings in these patients. Additionally, liver cirrhosis and a history of previous GIB increased the risk of GIB in patients with COVID-19.


  • Open Access

    The Protective Effect of Geraniol Against Hepatic Ischemia–Reperfusion Injury by Attenuating Oxidative Stress, Inflammatory Response, and Apoptosis in Rat Model

    by Seyedeh Mahdieh Khoshnazar, Foruzan Delavarian, Sahar Rahimi, Shahriar Dabiri, Nader Shahrokhi, Nazgol Sharifi, Sara Shafieipour

    Background: Hepatic ischemia–reperfusion injury (HIRI) is one of the main causes of hepatic fibrosis that occurs during liver surgery. This study aimed to investigate the protective effect of geraniol (GNL) against HIRI in a rat model. Methods: Wistar rats were randomly divided into seven groups and subjected to 45 min of hepatic ischemia, followed by either 60 min or 6 h of reperfusion. Immediately before reperfusion, graded doses of geraniol (50 and 100 mg/kg) were administered intraperitoneally. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured to evaluate liver function. Antioxidant enzyme activities were assessed in liver homogenates. The concentrations of TNF‐α, IL‐1β, Bax, and Bcl2 mRNA and proteins in liver tissue were measured using RT‐PCR and enzyme‐linked immunosorbent assay (ELISA). The expression of Bcl2 and caspase‐3 in liver tissue was evaluated by immunohistochemistry. In addition, liver tissue histopathology was examined under a light microscope. Results: The results demonstrated that liver damage significantly increased after repeated HIRI. However, treatment with GNL reduced hepatic enzyme levels and mitigated pathological changes resulting from repeated HIRI. Additionally, GNL treatment led to a decrease in apoptotic factors. Conclusion: GNL may be a potential therapeutic agent for preventing or treating hepatic fibrosis caused by ischemia–reperfusion injury.


  • Safety and Efficacy of Geraniol in Gastrointestinal System

    by Seyedeh Mahdieh Khoshnazar, Nazanin Zeinali, Mohammad Mohagheghi, Sara Shafieipour


  • Open Access

    Hepatitis B Virus (HBV) and Occult Hepatitis B Virus (OBI) in Hemodialysis Patients: An Epidemiological Observational Study in Kerman, Iran (2022-2023)

    by Mohsen Nakhaie, Sara Ahmadinejad Farsangi, Mohammad Rezaei Zadeh Rukerd, Sara Shafieipour, Nasir Arefinia, Mohammad Javad Zahedi, Shahab Mahmoudvand, Ehsan Taheri, Javad Charostad

    Background and Aim: Viral infections are associated with augmented morbidity and mortality risk in Hemodialysis (HD) patients. Materials and Methods: In this investigation, we have scrutinized the presence of hepatitis B virus (HBV), and occult hepatitis B virus infection (OBI), in HD patients. In this cross-sectional study, the blood samples and data from 200 ...


  • Open Access

    Prevalence of Hepatitis C Virus and Its Occult Infection in Hemodialysis Patients

    by Mohsen Nakhaie, Ehsan Taheri, Javad Charostad, Nasir Arefinia, Davood Kalantar-Neyestanaki, Mohammad Rezaei Zadeh Rukerd, Fatemeh Ahmadpour, Mohamad Hossein Pourebrahimi, Sara Ahmadinejad Farsangi, Sara Shafieipour

    Background: Hepatitis C virus (HCV) is one of the most common infections in hemodialysis patients, which has been associated with increased incidence of morbidity and mortality, particularly in low- and middle-income countries. Objectives: The current study aimed to evaluate the HCV antibody, occult HCV infection (OCI), and related risk factors among hemodialysis patients. Methods: In this cross-sectional study, 100 hemodialysis patients referred to a dialysis center in Kerman between December 2021 and March 2022 were assessed for HCV, OCI, and their related risk factors. The information related to risk factors was collected by questionnaire, while HCV and OCI were detected through serology and real-time polymerase chain reaction (PCR) methods, respectively. Results: Among the patients participating in the study, 61 were men, and 39 were women. The average age was 58.1 ± 14.9 years in men and 63.6 ± 11.4 years in women. Diabetes and hypertension history, old age, low education, self-employment, and urban living were more common in chronic kidney disease patients. The enzyme-linked immunosorbent assay (ELISA) revealed 3% positive seroprevalence HCV infection, but only 1% was positive for OCI. Although no statistically significant relationship was found between the presence of HCV (antibody and OCI) and other parameters, all positive HCV cases were identified in patients with low education and freelance employment. Conclusions: Hemodialysis patients had a low prevalence of HCV antibody and OCI. Improving various factors and conditions such as lifestyle, occupation, educational level, and dialysis ward and machine disinfection could be beneficial in managing and controlling hemodialysis complications such as HCV and OCI.


  • Open Access

    Cytotoxic Effects of Amaranth (Amaranthus caudatus L.) Extract on Human Hepatocyte Cell Lines

    by Mohammad Shafie, Bizhan Ahmadi, Ali Khosravi, Maryam Azimi, Ali Derakhshani, Ali Saeedpour, Sara Shafieepour, Motahareh Zaherara

    Background: Arbitrary unsuitable consumption of Amaranthus caudatus L. (amaranth) extract has been reported in some patients with acute liver failure who were referred to Kerman Medical Centers. Also, some studies on rats have shown the hepatotoxic effects of amaranth extracts by increasing liver enzymes and serum bilirubin. Objectives: This study was performed to determine the cytotoxic and lethal effects of amaranth extract on human hepatocytes. Methods: After preparing amaranth extract and hepatocyte cells, the cells were incubated in four culture media, including Dulbecco’s modified eagle medium (DMEM) and a control culture medium, with 10% fetal bovine serum (FBS) and penicillin, and streptomycin, and stored and frozen after growth and proliferation. Then the cells were exposed to 10, 50, 100, and 200 μg/mL dilutions of amaranth extract and incubated for 24 hours. Finally, the percentage of cell growth and proliferation was measured by cell survival tests, including MTT and neutral red assay, and flow cytometry. Results: Using MTT and neutral red assay and flow cytometry during different stages of increasing the dose of amaranth extract and evaluating the average light absorbance, it was shown that the culture medium containing a dose of 200 μg/mL of amaranth extract had the most cytotoxic and apoptotic effects on hepatocytes. Conclusions: Due to the hepatotoxic effect of amaranth plant extracts in toxic doses and induction of jaundice and acute liver failure in some patients, arbitrary consumption of this plant should be limited.

  • Open Access

    Higher Risk of Chronic Hepatitis E Virus infection in Patients with Human Immunodeficiency Virus-1: An Iranian Cross- sectional Study

    by Mohamad Javad Zahedi, Sara Shafieipour, Mohammad Mahdi Hayatbakhsh Abbasi, Nader Pourjamali, Mohsen Nakhaie, Javad Charostad, Mohammad Rezaei Zadeh Rukerd, Mohammad Mehdi Lashkarizadeh, Fatemeh Karami Robati, Azam Dehghani, et al.

    Background & Objective: Hepatitis E Virus (HEV) infection may be common in Human Immunodeficiency Virus (HIV-1) patients and may lead to chronic infection as well as cirrhosis. We intended to determine the incidence of HEV infection among HIV-1 patients in comparison to individuals without HIV-1 infection.Methods: In our cross-sectional study, 87 HIV-1-positive patients were compared to 93 healthy individuals in Kerman, Iran. Plasma and peripheral blood mononuclear cells (PBMCs) were obtained from all participants. Plasmas were evaluated for HEV IgM and IgG using the ELISA kit. Then, reverse transcriptase-nested polymerase chain reaction (RT-nested PCR) was used in RNA extractions from PBMCs to check for the presence of HEV RNA.Results: Among the subjects examined in our study, 61 (70.1%) and 71 (77.4%) out of patients with HIV-1 infection and healthy individuals were male, respectively. The average ages of patients with HIV-1 and the control group were 40.2 years and 39.9 years, respectively. No discernible differences existed between the two groups based on IgM and IgG seropositivity against the HEV. However, HEV-RNA was found in 8% of patients with HIV-1 and 1.1% of HIV-1-negative individuals (P=0.03). There was also an association between the HEV genome and anti-HEV and anti-HCV antibodies in HIV-1-positive patients (P=0.02 and P=0.014, respectively).Conclusion: HEV infection was more common in HIV-1 patients and may develop a chronic infection in immunocompromised individuals. Here, we suggest molecular-based HEV diagnostic tests, including RT-PCR assays, should be performed in HIV-1 patients with unknown impaired liver function tests.


  • Open Access

    Mortality Trends of Gastrointestinal, Liver, and Pancreaticobiliary Diseases: A Hospital-Based Prospective Study in the Southeast of Iran

    by Mohammad Javad Zahedi, Sara Shafieipour, Mohammad Mahdi Hayatbakhsh Abbasi, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Mohammad Mehdi Lashkarizadeh, Farbood Noorbini, Mohammad Hasan Baghaei, Abbas Pourjafari, Ebrahim Aminian, et al.

    Background: Gastrointestinal (GI), liver, and pancreaticobiliary diseases, in addition to the high health care utilization, account for a significant proportion of disability and death in Iran. We aimed to assess the incidence of in-hospital mortality for the total GI, liver, and pancreaticobiliary diseases in all hospitals in Kerman, Iran. Methods: In a cross-sectional study from May 2017 to April 2018, we collected the data of in-hospital death records due to GI, liver, and pancreaticobiliary diseases in all hospitals in Kerman city. GI and liver diseases were classified into three main categories: 1. Non-malignant GI diseases, 2. Non-malignant liver and pancreaticobiliary diseases, and 3. GI, liver, and pancreaticobiliary malignancies. All data were analyzed using SPSS software, version 22 (IBM). Results: Of 3427 in-hospital mortality, 269 (7.84%) deaths were due to GI, liver, and pancreaticobiliary diseases, of which 82 (30.48%) were related to non-malignant GI disorders, 92 (34.20%) to the non-malignant liver and pancreaticobiliary diseases, and 95 (35.31%) were associated with GI, liver and pancreaticobiliary malignancies. Most patients were male (62.08%), and the most common age was between 60-80 years (40.5%). GI bleeding occurred in 158 (58.73%) patients, and variceal bleeding was the most common cause (28.48%). Additionally, cirrhosis was reported in 41 out of 92 (44.56%), and hepatitis B virus (HBV) was the most common cause of cirrhosis among 17 out of 41 (41.46%). Conclusion: Our results show that gastric, colorectal, and pancreatic cancers and cirrhosis due to HBV were the most common causes of mortality associated with GI, liver, and pancreaticobiliary diseases in the hospitals of Kerman.


  • Structural analysis of misfolding equilibrative nucleoside transporter 3in H-syndrome

    by Nahid Askari, Elham Rezvannejad, Sodaif Darvish Moghadam, Sara Shafieipour